Erdafitinib

Evidence Level: L5

Predicted Indications: 6

Erdafitinib

Pharmacist Assessment Report

Erdafitinib: From Its Marketed Use to Pulmonary Hypertension

One-Sentence Summary

Erdafitinib is a pan-FGFR (FGFR1-4) tyrosine kinase inhibitor marketed in Canada as BALVERSA. The approved indication text is not available in the data compiled for this report. The TxGNN model predicts it may be effective for pulmonary hypertension, but there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not available in the data compiled for this report
Predicted New Indication	Pulmonary hypertension
TxGNN Prediction Score	0.9938
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 3 of 3)
Number of DINs	3 (marketed: 3)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, erdafitinib is a pan-FGFR (FGFR1-4) tyrosine kinase inhibitor.

FGF/FGFR signaling has been implicated in pulmonary vascular remodeling and smooth muscle proliferation. This offers a plausible but unvalidated rationale for pulmonary hypertension. The TxGNN score is very high (0.9938, rank 10,953), but it is a model prediction only.

Safety is a concern. FGFR inhibitors are known to cause hyperphosphatemia, ocular toxicity, and nail and skin effects. The net benefit in a cardiopulmonary population is unknown.

Other predictions in the top 10 are weaker or lack a clear mechanistic link:

Rheumatoid arthritis is the only one with any literature. That literature is a general kinase inhibitor review, not RA-specific evidence.
Kyphoscoliotic heart disease, amenorrhea, ALS (and related entries), brachydactyly-syndactyly syndrome, axial spondylometaphyseal dysplasia, and Mills syndrome have no supporting trials or literature.
For several of these, inhibiting FGFR could be ineffective or even harmful.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for pulmonary hypertension.

The only literature in the top 10 predictions is for rheumatoid arthritis (rank 4). It is general context, not evidence of efficacy:

PMID	Year	Type	Journal	Key Findings
31862477	2020	Review	Pharmacological Research	2020 update on properties of FDA-approved small molecule kinase inhibitors, including erdafitinib. It has no RA-specific clinical data.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02493233	BALVERSA	Not specified	Not specified
02493225	BALVERSA	Not specified	Not specified
02493217	BALVERSA	Not specified	Not specified

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (kinase inhibitor, FGFR1-4)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Serum phosphate, ocular examination, and skin and nail assessment, based on the known class effects of FGFR inhibitors. Please also refer to the package insert.
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: The interaction screen was completed and returned 100 interacting drugs. The 20 entries reviewed include:
- Major: cholecalciferol, calcitriol, calcifediol, calcium phosphate, calcium acetate, dexamethasone, clarithromycin, magnesium oxide, magnesium sulfate, magnesium chloride.
- Moderate: metformin, loperamide, saxagliptin, linagliptin, empagliflozin, eliglustat, naldemedine, naloxegol, prucalopride, rifaximin.
Class-related concerns: Hyperphosphatemia, ocular toxicity, and nail and skin effects are known with FGFR inhibitors. The interactions with vitamin D and calcium or phosphate-containing products are consistent with the phosphate-related concern.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for pulmonary hypertension has a very high model score but no clinical trials or literature behind it (evidence level L5). The mechanistic rationale is plausible but unvalidated. The known toxicity profile of FGFR inhibitors adds uncertainty for a cardiopulmonary population.

To proceed, the following is needed:

Health Canada package insert warnings, contraindications, and approved indications (a blocking gap for safety screening)
Detailed mechanism of action data
Preclinical evidence for FGFR inhibition in pulmonary vascular remodeling
A benefit-risk assessment of hyperphosphatemia, ocular, and skin and nail toxicity in patients with pulmonary hypertension
Review of the major drug interactions, particularly with vitamin D, calcium, and magnesium products
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.